CD40 ligand induces an antileukemia immune response in vivo

Blood

Volumn 90, Issue 5, 1997, Pages 1927-1933

  Dilloo, Dagmar ^a   Brown, Michael ^a   Roskrow, Marie ^a   Zhong, Wanyung ^a   Holladay, Martha ^a   Holden, William ^a   Brenner, Malcolm ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; IMMUNOGENICITY; LEUKEMIA; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030984036     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.5.1927     Document Type: Article

References (47)

1. Henderson RA, Finn OJ: Human tumor antigens are ready to fly. Adv Immunol 62:217, 1996
2. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065, 1992
3. + T cells by B7-transfected melanoma cells. Science 259:368, 1993
4. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK: CD40 expression by human monocytes: Regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 178:669, 1993
5. Freudenthal PS, Steinman RM: The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci USA 87:7698, 1990
6. Caux C, Massierter C, Vanbervliet B, Dubois B, Kooten CV, Durand I, Banchereau J: Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180:1263, 1994
7. Cayabyab M, Phillips JH, Lanier LL: CD40 perferentially co-stimulates activation of CD4+ T lymphocytes. J Immunol 152:1523, 1994
8. Wagner DH, Stout RD, Suttles J: Role of the CD40-CD40 ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur J Immunol 24:3148, 1994
9. Fanslow WC, Clifford KN, Seaman M, Alderson MR, Spriggs MK, Armitage RJ, Ramsdell F: Recombinant CD40 ligand exerts potent biologic effects on T cells. J Immunol 152:4262, 1994
10. Armitage RJ, Tough TW, Macduff BM, Fanslow WC, Spriggs MK, Ramsdell F, Alderson MR: CD40 ligand is a T cell growth factor. Eur J Immunol 23:2326, 1993
11. Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 76:241, 1994
12. Fearon ER, Pardoe DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397, 1990
13. Maass G, Schmidt W, Berger M, Schilcher F, Koszik F, Schneeberger A, Stingl G, Birnsteil M, Schweighoffer T: Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 92:5540, 1995
14. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E: Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217, 1990
15. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R: Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 122:549, 1979
16. Patek PQ, Collins JL, Cohn M: Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis. Nature 276:510, 1978
17. Friedman KD, Rosen NL, Newman PJ, Montgomery RR: Screening of 1gt1 1 libraries, in Innis MA, Gelfand DH, Sninsky JJ, White TJ (eds): PCR Protocols: A Guide to Methods and Applications. New York, NY, Academic, 1990, p 254
18. Coleclough C: Cell-free expression of large collections of cDNA clones using positive-selection I phage vectors. Methods Enzymol 217:152, 1993
19. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T, Maliszewski CR, Clark EA, Smith CA, Grabstein KH, Cosman D, Spriggs MK: Molecular and biological characterization of a murine ligand for CD40. Nature 357:80, 1992
20. Pear WS, Nolan GP, Scott ML, Baltimore D: Production of high-liter helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90:8392, 1993
21. Bender MA, Palmer TD, Gelinas RE, Miller AD: Evidence that the packaging signal of Moloney Murine Leukemia Virus extends into the gag region. J Virol 61:1639, 1987
22. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, IhIe JN: Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342:1134, 1993
23. Brenner MK, Furman WL, Santana VM, Bowman L, Meyer W: Phase I study of cytokine-gene modified autologous neuroblastoma. Hum Gene Ther 3:665, 1992
24. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR, Pierres M, Fitch FW: Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 131:2445, 1983
25. Sarmiento M, Glasebrook AL, Fitch FW: IgG of IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing LYT 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 125:2665, 1980
26. Ogasawara J, Suda T, Nagata S: Selective apoptosis of CD4+CD8+ thymocytes by the Anti-Fas antibody. J Exp Med 181:485, 1995
27. Yang Y, Wilson JM: CD40 ligand-dependent T cell activation: Requirement of B7-CD28 signaling through CD40. Science 273:1862, 1996
28. Natoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, Balsano C, Levrero M: Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 11:1157, 1995
29. Weller M, Malipiero U, Rensing-Ehl A, Barr PJ, Fontana A: Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 55:2936, 1995
30. Ogasawara J, Suda T, Nagata S: Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody. J Exp Med 181:485, 1995
31. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS, Woo SL: Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 92:2577, 1995
32. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54:6228, 1994
33. Tepper RI, Mule JJ: Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 5:153, 1994
34. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093, 1992
35. Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD: Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85:2507, 1995
36. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM: Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261, 1994
37. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan R: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539, 1993
38. Ranheim EA, Kipps TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 177:925, 1993
39. Shultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM: Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity. Immunology 92:8200, 1995
40. Vyth-Dreese FA, Dellemijn TAM, van Oostveen JW, Feltkamp CA, Hekman A: Functional expression of adhesion receptors and costimulatory molecules by fresh and immortalized B-cell nonHodgkin's lymphoma cells. Blood 85:2802, 1995
41. Cardosa AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszio S, Billet A, Sallan SE, Gribben JG, Nadler LM: Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 88:41, 1996
42. Schattner EJ, Elkon KB, Yoo DH, Tumang J, Krammer PH, Crow MK, Friedman SM: CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 182:1557, 1995
43. Schattner EJ, Mascarenhas J, Bishop J, Yoo DH, Chadburn A, Crow MK, Freidman SM: CD4(+) T-cell induction of FAS-mediated apoptosis in Burkitts lymphoma B cells. Blood 88:1375, 1996
44. Nagata S, Goldstein P: The fas death factor. Science 267:1449, 1995
45. Elder EM, Lotze MT, Whiteside TL: Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum Gene Ther 7:479, 1996
46. Veelken H, Mackenson A, Lahn M, Kohler G, Becker D, Franke B, Brennscheidt U, Kulmburg P, Rosenthal FM, Keller H, Hasse J, Schultzeseemann W, Farthmann EH, Mertelsmann R, Lindemann A: A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 70:269, 1997
47. Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT: Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 26:1335, 1996